Is PULSE BIOSCIENCES, INC. (PLSE) Halal?

NASDAQ Healthcare United States $1.4B
✓ HALAL
Confidence: 83/100
PULSE BIOSCIENCES, INC. (PLSE) is Halal under 3 of 5 Shariah screening standards, including AAOIFI Standard 21. With a debt ratio of just 0.7% against the AAOIFI threshold of 30%, PULSE BIOSCIENCES, INC. comfortably passes the key financial ratio tests. The company operates in the Healthcare sector (Medical Instruments & Supplies), which is not a prohibited industry under Islamic finance principles.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 0.7%
/ 30%
9.6%
/ 30%
0.0%
/ 30%
N/A ✓ HALAL
DJIM 0.7%
/ 33%
9.6%
/ 33%
0.0%
/ 33%
N/A ✓ HALAL
MSCI 6.7%
/ 33%
89.1%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
S&P 0.7%
/ 33%
9.6%
/ 33%
0.0%
/ 33%
N/A ✓ HALAL
FTSE 6.7%
/ 33%
89.1%
/ 33%
0.0%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-1.08
P/B Ratio
17.3
EV/EBITDA
-17.5
EV: $1.3B
Revenue
$350,000
Beta
1.8
High volatility
Current Ratio
10.5

Profitability

Gross Margin -54.0%
Operating Margin -6914.0%
Net Margin 0.0%
Return on Equity (ROE) -74.4%
Return on Assets (ROA) -42.4%

Cash Flow & Balance Sheet

Operating Cash Flow-$54M
Free Cash Flow-$54M
Total Debt$8M
Debt-to-Equity9.3
Current Ratio10.5
Total Assets$95M

Price & Trading

Last Close$21.50
50-Day MA$19.09
200-Day MA$16.48
Avg Volume334K
Beta1.8
52-Week Range
$12.56
$26.30

About PULSE BIOSCIENCES, INC. (PLSE)

CEO
Mr. Paul Arthur LaViolette
Employees
116
Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States
Exchange
NASDAQ
Market Cap
$1.4B
Currency
USD

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is PULSE BIOSCIENCES, INC. (PLSE) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), PULSE BIOSCIENCES, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is PULSE BIOSCIENCES, INC.'s debt ratio?

PULSE BIOSCIENCES, INC.'s debt ratio is 0.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 6.7%.

What are PULSE BIOSCIENCES, INC.'s key financial metrics?

PULSE BIOSCIENCES, INC. has a market capitalization of $1.4B, and revenue of $350,000. Return on equity stands at -74.4%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.